names of glp-1 medications mentioned by the WHO. The World Health Organization released its first global guideline on using GLP-1 medicines for obesity, emphasizing safe, appropriate, provider-guided care. DM for consultation 🤍 #GLP1 #WHOGuidelines # What's the Difference Between Brand-Name

Joint pain during tirzepatide treatment may result from rapid weight loss altering biomechanics and joint loading, increased physical activity unmasking pre-existing joint issues, or underlying conditions like osteoarthritis that are common in patients with obesity and type 2 diabetes

The popularity of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has increased in recent years (Rodriguez et al., 2023)

doi: 10.1691/ph.2011.0835 85 WangHBouzakouraSde MeySJiangHLawKDufaitIet al

Unstable angina pectoris: An umbrella review of meta-analyses of RCTs including 56,004 patients with diabetes, prediabetes, and at high risk of diabetes, found no association between GLP-1 RAs and the risk of uAP (RR = 1.06, 95%CI = 0.931.21) when compared to placebo (Zhu et al., 2020)

Note that there are many different types of inhalers

Pharmacology Made Incredibly Easy (Incredibly Easy